Search Results - nucleotide

5 Results

Sort By:

Potent Nucleotide Inhibitors of Ecto-5'-Nucleotidase (CD73)

These small molecules are novel nucleotide derivatives, containing either a purine or pyrimidine nucleobase, that competitively block the enzyme CD73, also known as ecto-5'-nucleotidase. This enzyme converts extracellular AMP (not a potent activator of adenosine receptors) to adenosine (the native activator of 4 subtypes of adenosine receptors. CD73...

Published: 7/25/2024 | Inventor(s): Christa Mueller, Anna Junker, Kenneth Jacobson

Keywords(s): CB5EXX, CD73, Ecto-5-nucleotidase, Inhibitors, Nucleotide, POTENT

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Probe Set Global Optimization

Available for licensing and commercial development are methods to optimize sequence-based assays such as microarrays, multiplexed PCR or multiplexed antibody methods. This computational method uses numerical optimization to identify an optimal probe set to be used in an assay for the measurement of a specified set of targets. The method incorporates...

Published: 4/8/2024 | Inventor(s): Kevin Brown, Eric Billings

Keywords(s): AA5XXX, AAXXXX, AC4XXX, ACXXXX, assay, AXXXXX, Bacterial, CA1AXX, CA1XXX, CAXXXX, computer methods, CXXXXX, DAXXXX, DXXXXX, Global, IAXXXX, IXXXXX, Nucleotide, OPTIMIZATION, PATHOGEN, Probe, probe set, Protein, SELECTION, Sequences, splice variants, VIRAL DIAGNOSTIC

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology

Development of Dengue Virus Type 3 Vaccine Candidates

The disease burden associated with dengue virus infection has increased over the past several decades in the tropical and semi-tropical regions of the world, where over 2 billion people live at risk of dengue infection. Annually, there are an estimated fifty (50) to one hundred (100) million cases of dengue fever, making development of an effective...

Published: 7/25/2024 | Inventor(s): Joseph Blaney, Brian Murphy, Stephen Whitehead

Keywords(s): 1, 2, 3, 30, 3'-UTR, CANDIDATES, CONSISTING, Containing, Contiguous, DA4BXX, DA4XXX, DAXXXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, Deletion, DELETIONS, Delta30, DEN4, DENGUE, Dengue (Flaviviridae), DENGUE FEVER, Dervived, Development, DXXXXX, Either, Genome, Hepatitis A, Hepatitis D, Hepatitis E, Iin, MULTIPLE, Nucleotdies, Nucleotide, ONE, Q fever, Regions, THAN, TYPE, UAXXXX, UBXXXX, Vaccine, virus

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Infectious Disease

Attenuated Human Parainfluenza Virus (PIV) for Use as Live, Attenuated Vaccines and as Vector Vaccines

The identified technologies describe self-replicating infectious recombinant paramyxoviruses with one or more attenuating mutations, such as a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein, or at least one temperature sensitive mutation and one non-temperature sensitive mutation....

Published: 7/25/2024 | Inventor(s): Peter Collins, Sheila Nolan, Mario Skiadopoulos, Brian Murphy

Keywords(s): cDNA, CIS-ACTING, Complete, DC5BXX, DC5XXX, DCXXXX, Determination, DXXXXX, FOR..., FRAMES, Gene, Generate, Generation, Genomic, HPIV2, HPIV2., HPIV2/V94, Identification, MEASLES, Mumps, MUTATION, Novel, Nucleotide, Overlapping, P/V, Parainfluenza virus type 3, Parainfluenza virus type 3; Human parainfluenza virus type 3, Reading, recombinant, rHPIV2, Separated, sequence, Strain, UA1XXX, USEFUL, V94

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Vaccines, TherapeuticArea > Infectious Disease

Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4

The invention relates to a dengue virus tetravalent vaccine containing a common 30-nucleotide deletion (delta30) in the 3'-untranslated region (UTR) of the genome of dengue virus serotypes 1, 2, 3, and 4. The previously identified delta30 attenuating mutation, created in dengue virus type 4 (DEN4) by the removal of 30 nucleotides from the 3'-UTR, is...

Published: 7/25/2024 | Inventor(s): Brian Murphy, Lewis Markoff, Barry Falgout, Kathryn Hanley, Joseph Blaney, Stephen Whitehead

Keywords(s): 3'-UTR, ANTIGENIC, chimeric, Chromosome 7, monosomy, DA4BXX, DA4XXX, DAXXXX, DB4BXX, DB4XXX, DBXXXX, DC5BXX, DC5XXX, DCXXXX, Deletion, Deletion 7, DENGUE, Dengue (Flaviviridae), DXXXXX, Nucleotide, Tetravalent, UAXXXX, UBXXXX, Vaccine, Viruses

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines